However, in our gliosarcoma patient with disease progression under entrectinib, no secondary NTRK mutation was detected, but molecular profiling revealed activation of alternative oncogenic pathways, including NF2 and insulin receptor (INSR). Here, INSR is linked to gliosarcoma.